Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide
| Autor: | Theodora Hadjistilianou, Francis L. Munier, Carol L. Shields, Y. Pierre Gobin, Pascal Jabbour, Sandra Bracco, Guillermo L. Chantada, Marcio Chaves Pedro Marques, Francesco Puccinelli, Alejandro Ceciliano, Luiz F. Teixeira, David H. Abramson, José Roberto Falco Fonseca |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Melphalan
medicine.medical_specialty medicine.medical_treatment Intraocular Retinoblastoma Retrospective data Metastatic death 03 medical and health sciences 0302 clinical medicine lcsh:Ophthalmology medicine.artery Intra-arterial (intrarterial) chemotherapy (IAC) Ophthalmic artery chemosurgery (OAC) Retinoblastoma (Rb) Medicine Chemotherapy business.industry Retinoblastoma Incidence (epidemiology) medicine.disease 3. Good health Surgery Intraarterial chemotherapy Ophthalmology lcsh:RE1-994 030220 oncology & carcinogenesis Ophthalmic artery Commentary 030221 ophthalmology & optometry business medicine.drug |
| Zdroj: | International Journal of Retina and Vitreous, Vol 3, Iss 1, Pp 1-4 (2017) International journal of retina and vitreous, vol. 3, pp. 40 International Journal of Retina and Vitreous |
| ISSN: | 2056-9920 |
| Popis: | Background Ophthalmic artery chemosurgery [OAC, intra-arterial chemotherapy (IAC)] was introduced in 2006 as treatment modality for intraocular retinoblastoma. The purpose of this commentary is to retrospectively review the incidence of metastatic deaths in retinoblastoma patients treated with OAC worldwide over a 10 year period. Retrospective data regarding metastatic deaths was collected from six international retinoblastoma centers (New York City USA, Philadelphia USA, Sao Paulo Brazil, Siena Italy, Lausanne Switzerland and Buenos Aires Argentina). All retinoblastoma patients from these centers (naive and recurrent, unilateral and bilateral) treated with OAC/IAC since 2006 have been included in this study. Data regarding number of patients, number of OAC/IAC infusions, number unilateral and bilateral, number treated for naive disease or salvage and number of metastatic deaths have been assessed. Over a 10-year period of time 1139 patients received OAC/IAC for 4396 infusions. At last follow-up there were only three metastatic deaths (all treated in Buenos Aires). Conclusion The current survey assessed the recorded risk of metastatic deaths in six retinoblastoma centers worldwide in children with retinoblastoma (unilateral or bilateral) treated with OAC/IAC as primary or secondary therapy. Overall, the observed risk for metastatic deaths from retinoblastoma was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink